Penumbra in the Pivotal Point Check: Innovative Medical Technology Manufacturer Impresses With Strong Thrombectomy Business - UBS Issues Buy Recommendation After Q4 Results!
Reading Time: 2 minutes
The US thrombectomy business recorded significant growth in Q4 with an increase of 27.3% compared to the previous year. UBS has raised its price target for Penumbra from $305 to $320 and reaffirmed its buy rating for the medical technology company's shares. Revenue is expected to grow by 12 to 14% in 2025, and the gross margin is projected to exceed 67%. On Tuesday, February 18, 2025, Penumbra reported strong financial results for Q4 2024 with earnings per share of $0.97, exceeding the forecast of $0.90. The company achieved revenue...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
